| 000 | 01637 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250515091627.0 | ||
| 264 | 0 | _c20080416 | |
| 008 | 200804s 0 0 eng d | ||
| 022 | _a0306-5251 | ||
| 024 | 7 |
_a10.1111/j.1365-2125.2007.02956.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJoerger, M | |
| 245 | 0 | 0 |
_aSafety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. _h[electronic resource] |
| 260 |
_bBritish journal of clinical pharmacology _cNov 2007 |
||
| 300 |
_a622-33 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xadverse effects |
| 650 | 0 | 4 |
_aBilirubin _xblood |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLiver Diseases _xcomplications |
| 650 | 0 | 4 |
_aLiver Function Tests _xmethods |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPaclitaxel _xadverse effects |
| 650 | 0 | 4 | _aSex Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aHuitema, A D R | |
| 700 | 1 | _aHuizing, M T | |
| 700 | 1 | _aWillemse, P H B | |
| 700 | 1 | _ade Graeff, A | |
| 700 | 1 | _aRosing, H | |
| 700 | 1 | _aSchellens, J H M | |
| 700 | 1 | _aBeijnen, J H | |
| 700 | 1 | _aVermorken, J B | |
| 773 | 0 |
_tBritish journal of clinical pharmacology _gvol. 64 _gno. 5 _gp. 622-33 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2125.2007.02956.x _zAvailable from publisher's website |
| 999 |
_c17456151 _d17456151 |
||